ADRO - Aduro BioTech, Inc.
| Previous Close | 4.0800 |
| Open | 4.0800 |
| Bid | 4.09 x 4000 |
| Ask | 4.25 x 1000 |
| Day's Range | 3.9400 - 4.2400 |
| 52 Week Range | 2.3400 - 9.9250 |
| Volume | 1,572,708 |
| Avg. Volume | 1,050,660 |
| Market Cap | 324.763M |
| Beta (3Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.22 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- Zacks•yesterday
What's in Store for Vericel (VCEL) This Earnings Season?
On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.
- Zacks•3 days ago
Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.
- GlobeNewswire•3 days ago
Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference
BERKELEY, Calif., Feb. 21, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is.
- GlobeNewswire•3 days ago
Aduro Announces Changes to its Board of Directors
Aduro Biotech, Inc. (ADRO) today announced the appointment of David H. Mack, Ph.D., President and CEO of PMV Pharmaceuticals, to its Board of Directors effective February 19, 2019. “As we advance our first-in-class STING and APRIL product candidates through the clinic, David’s strategic approach to drug development in oncology coupled with his exceptional leadership skills will be tremendously valuable and we look forward to his guidance and contributions,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “On behalf of the Board, shareholders and employees, I would also like to thank and recognize Frank for his support over the last nine years, which helped to shape Aduro and its core technologies from our founding to where we are today.
- Zacks•4 days ago
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.
- Zacks•4 days ago
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
- Zacks•5 days ago
What's in Store for Sangamo (SGMO) This Earnings Season?
On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.
- Zacks•9 days ago
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
- GlobeNewswire•10 days ago
Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•10 days ago
Will Aduro Biotech Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Aduro Biotech.
- Zacks•11 days ago
5 Tiny Biotech Stocks With Superb Growth Potential
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
- Zacks•11 days ago
Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100
Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.
- Zacks•12 days ago
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
- Zacks•13 days ago
Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?
Merrimack (MACK) regains its status as a development-stage biopharma company after the sale of its sole marketed product Onivyde in 2017.
- GlobeNewswire•13 days ago
Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma
Aduro Biotech, Inc. (ADRO) today announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 (MIW815), a novel stimulator of interferon genes (STING) pathway activator, in combination with YERVOY® (ipilimumab), an approved anti-CTLA-4 antibody for the treatment of relapsed and refractory melanoma. The multicenter trial (see www.clinicaltrials.gov, identifier: NCT02675439), which is part of an ongoing research and development collaboration with Novartis, will enroll advanced melanoma patients who have relapsed after or are refractory to treatment with anti-PD-1 antibodies, nivolumab or pembrolizumab. “We are pleased to initiate this study evaluating ADU-S100 with ipilimumab in a homogeneous patient population.
- Zacks•16 days ago
AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates
AMAG encourages with narrower-than-expected loss in Q4 while revenues fall shy of estimates.
- Zacks•18 days ago
Top Ranked Momentum Stocks to Buy for February 6th
Top Ranked Momentum Stocks to Buy for February 6th
- American City Business Journals•24 days ago
Why are deep-pocketed biotechs cutting hundreds of jobs?
Biotech companies' reasons differ for 600 job cuts over the past few months, but the numbers are jarring for an industry at the intersection of a strong cash position and groundbreaking science.
- GlobeNewswire•25 days ago
Aduro Biotech Announces Strategic Reset
Aduro Biotech, Inc. (ADRO) today announced a strategic reset to focus on Aduro’s core strengths – discovery and development of novel product candidates in the stimulator of interferon genes (STING) and a proliferation inducing ligand (APRIL) pathways. Aduro is partnered with Novartis for STING pathway activators in oncology, including ADU-S100 (MIW815), and Eli Lilly and Company (Lilly) for cGAS-STING pathway inhibitors in autoimmune and inflammatory diseases. BION-1301, a first-in-class anti-APRIL antibody, is currently in development in oncology and IgA nephropathy.
- Simply Wall St.•29 days ago
Is Aduro BioTech, Inc. (NASDAQ:ADRO) A Volatile Stock?
If you're interested in Aduro BioTech, Inc. (NASDAQ:ADRO), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
- Zacks•last month
Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
- Zacks•last month
Vertex Terminates COO Ian Smith on Code of Conduct Violation
Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.
- Zacks•last month
Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition
Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.
